Also available in Persian — نسخه فارسی EN فا
❓ Unknown

Production of Cheap Medicines in Developing Countries Faces Opposition from the U.S.

Feb 11, 2026 February 11, 2026 1 min read 📰 VOA Persian
📋 Key Takeaway

The U.S. blocked a resolution at the WTO that would have allowed developing countries to produce affordable medicines for serious diseases. This action has drawn criticism, suggesting it is influenced by American pharmaceutical companies. The situation highlights ongoing tensions between public health needs and intellectual property rights.

🔍 Quick Context Guide
💡 Bottom Line: The U.S. blocking the resolution underscores the conflict between pharmaceutical interests and the urgent need for affordable healthcare in developing nations.

👥 Key Players

United States MENTIONED
Opposing member at the WTO
"The U.S. plays a significant role in global trade policies and intellectual property rights, impacting access to medicines worldwide."
World Trade Organization (WTO) MENTIONED
International trade body
"The WTO facilitates trade negotiations and agreements among its member countries, influencing global economic policies."
Pharmaceutical Companies MENTIONED
Industry stakeholders
"These companies influence drug pricing and availability, affecting public health and access to medicines."

📰 What Happened

The U.S. blocked a resolution at the WTO that would have allowed developing countries to produce affordable medicines for serious diseases. This action has sparked criticism regarding the influence of pharmaceutical companies on U.S. policy.

  • The resolution aimed to enable developing countries to produce generic versions of essential medicines.
  • The U.S. is the only country opposing this resolution among 144 WTO members.

💡 Why It Matters

🇮🇷 For Iran: Iran, facing sanctions and limited access to medicines, could benefit from affordable drug production, making this U.S. opposition particularly relevant.
🌍 Regional: Other developing countries may struggle to access affordable medicines, affecting public health in the region.
🌐 International: This situation highlights the tension between protecting intellectual property and ensuring global health equity.

📚 Background

Developing countries often rely on generic medicines to treat serious diseases due to high costs of patented drugs. The U.S. stance reflects broader issues of intellectual property rights in global health.

Intellectual Property Rights Global Health Access
📡 Source: INTERNATIONAL
📊 Confidence: 70%
The article presents a critical view of U.S. actions, suggesting potential bias against U.S. pharmaceutical interests.

The United States prevented the approval of a draft resolution presented at the World Trade Organization. Under this proposal, developing countries would have been allowed to produce cheap medicines similar to those used for serious and dangerous diseases. The United States is the only opposing member in this organization, which has 144 member countries. The U.S. believes that the approval of this plan disregards the rights arising from drug patents. Critics accuse the U.S. of being influenced by large pharmaceutical companies in America.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 85%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →